Definition and prevalence over the years of polypharmacy in Turkey: A systematic review

Cansu Göncüoğlu; Nesligül Özdemir; Emre Kara; Aygin Ekincioğlu

Definition and prevalence over the years of polypharmacy in Turkey: A systematic review

Abstract

Background: Identification of the trend of polypharmacy over the years is as valuable as determining the common definitions for taking precautions. The aim of this systematic review is to reveal the frequency, commonly used definitions and its change over the years of polypharmacy in Turkey. Methods: The reporting of this systematic review follows to the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA 2020) checklist. The MEDLINE and ULAKBIM TR Dizin databases were searched for relevant studies published until April, 2021. The studies conducted with patients >18 years in Turkey were included. Results: A total of 361 articles were identified and 52 articles met the inclusion criteria. The most common definition of polypharmacy was ‘combination of 5 or more drugs’, followed by the definitions of ‘two or more drugs’ to ‘10 or more drugs’’; and its prevalence ranged between 9% and 95% in the studies. Conclusions: It was determined that the most commonly used definition of polypharmacy was ‘the use of 5 or more drugs’. The prevalence of polypharmacy in Turkey was appeared in a wide range and found higher than the studies in the literature. The prevalence and trends of polypharmacy over the years should be carefully observed, inappropriate use of medicines should be examined and necessary precautions should be taken accordingly.

Keywords

References

[1] World Health Organization. Medication Safety in Polypharmacy. Geneva: 2019 Contract No.: Licence: CC BY-NC-SA 3.0 IGO.
[2] Pesante-Pinto JL. Clinical pharmacology and the risks of polypharmacy in the geriatric patient. Phys Med Rehabil Clin N Am. 2017;28(4):739-746. https://doi.org/10.1016/j.pmr.2017.06.007.
[3] Fincke BG, Snyder K, Cantillon C, Gaehde S, Standring P, Fiore L, Brophy M, Gagnon DR. Three complementary definitions of polypharmacy: methods, application and comparison of findings in a large prescription database. Pharmacoepidemiol Drug Saf. 2005;14(2):121-128. https://doi.org/10.1002/pds.966.
[4] Grimmsmann T, Himmel W. Polypharmacy in primary care practices: an analysis using a large health insurance database. Pharmacoepidemiol Drug Saf. 2009;18(12):1206-1213. https://doi.org/10.1002/pds.1841.
[5] Stewart RB, Cooper JW. Polypharmacy in the aged. Practical solutions. Drugs Aging. 1994;4(6):449-461. https://doi.org/10.2165/00002512-199404060-00002.
[6] Weng MC, Tsai CF, Sheu KL, Lee YT, Lee HC, Tzeng SL, Ueng KC, Chen CC, Chen SC. The impact of number of drugs prescribed on the risk of potentially inappropriate medication among outpatient older adults with chronic diseases. QJM. 2013;106(11):1009-1015. https://doi.org/10.1093/qjmed/hct141.
[7] Col N, Fanale JE, Kronholm P. The role of medication noncompliance and adverse drug reactions in hospitalizations of the elderly. Arch Intern Med. 1990;150(4):841-845.
[8] Juurlink DN, Mamdani M, Kopp A, Laupacis A, Redelmeier DA. Drug-drug interactions among elderly patients hospitalized for drug toxicity. JAMA. 2003;289(13):1652-1658. https://doi.org/10.1001/jama.289.13.1652.

[9] Suggett E, Marriott J. Risk factors associated with the requirement for pharmaceutical intervention in the hospital setting: A systematic review of the literature. Drugs Real World Outcomes. 2016;3(3):241-263. https://doi.org/10.1007/s40801-016-0083-4.
[10] Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, Farrar K, Park BK, Breckenridge AM. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ. 2004;329(7456):15-19. https://doi.org/10.1136/bmj.329.7456.15.
[11] Davies EC, Green CF, Taylor S, Williamson PR, Mottram DR, Pirmohamed M. Adverse drug reactions in hospital in-patients: a prospective analysis of 3695 patient-episodes. PLoS One. 2009;4(2):e4439. https://doi.org/10.1371/journal.pone.0004439.
[12] Gokce Kutsal Y, Barak A, Atalay A, Baydar T, Kucukoglu S, Tuncer T, Hizmetli S, Dursun N, Eyigor S, Saridogan M, Bodur H, Canturk F, Turhanoglu A, Arslan S, Basaran A. Polypharmacy in the elderly: a multicenter study. J Am Med Dir Assoc. 2009;10(7):486-490. https://doi.org/10.1016/j.jamda.2009.03.018.
[13] Bahat G, Tufan F, Bahat Z, Aydin Y, Tufan A, Akpinar TS, Erten N, Karan MA. Assessments of functional status, comorbidities, polypharmacy, nutritional status and sarcopenia in Turkish community-dwelling male elderly. Aging Male. 2013;16(2):67-72. https://doi.org/10.3109/13685538.2013.771329.
[14] Nobili A, Licata G, Salerno F, Pasina L, Tettamanti M, Franchi C, De Vittorio L, Marengoni A, Corrao S, Iorio A, Marcucci M, Manucci PM. Polypharmacy, length of hospital stay, and in-hospital mortality among elderly patients in internal medicine wards. The REPOSI study. Eur J Clin Pharmacol. 2011;67(5):507-519. https://doi.org/10.1007/s00228-010-0977-0.
[15] Kantor ED, Rehm CD, Haas JS, Chan AT, Giovannucci EL. Trends in prescription drug use among adults in the United States From 1999-2012. JAMA. 2015;314(17):1818-1831. https://doi.org/10.1001/jama.2015.13766.
[16] Kwak MJ, Chang M, Chiadika S, Aguilar D, Avritscher E, Deshmukh A, Goyal P, Kim DH, Aparasu R, Holmes HM. Healthcare expenditure associated with polypharmacy in older adults with cardiovascular diseases. Am J Cardiol. 2022;169:156-158. https://doi.org/10.1016/j.amjcard.2022.01.012.
[17] Dişçigil G, Tekinç N, Anadol Z, Bozkaya AO. Polypharmacy in nursing home and community-dwelling elderly. Turk J Geriatr. 2006;9(3):117-121.
[18] Çakmur H. Factors affecting polypharmacy in elderly in two different (Kars-Izmir) cities of turkey. Türkiye Klinikleri J Med Sci. 2014;34(1):71. https://doi.org/10.5336/medsci.2013-36059.
[19] Sönmez Y, Aşçı H, Olgun İzmirli G, Gündoğar D, Cankara FN, Yeşilot Ş. Evaluation of potentially inappropriate drug use and medical non-adherence in a community-dwelling elderly population: a cross-sectional study. Turk J Geriatr. 2014;17(2): 125-133.
[20] Bahat G, Tufan F, Bahat Z, Tufan A, Aydin Y, Akpinar TS, Nadir S, Erten N, Karan MA. Comorbidities, polypharmacy, functionality and nutritional status in Turkish community-dwelling female elderly. Aging Clin Exp Res. 2014;26(3):255-259. https://doi.org/10.1007/s40520-014-0229-8.
[21] Taşkın Şayir Ç, Aslan Karaoğlu S, Evcik Toprak D. Evaluation of polypharmacy and complementary therapy use in patients? 65 years, attending to family medicine outpatient clinic of Şişli Etfal Training And Research Hospital. Türk Aile Hek Derg. 2014;18(1): 35-41. https://doi.org/10.2399/tahd.14.35220.
[22] Yuruyen M, Yavuzer H, Demirdag F, Kara Z, Cengiz M, Yavuzer S, Doventas a, Erdincler DS, Beger T. Is depression a predictive factor for polypharmacy in elderly? Klinik Psikofarmakol Bulteni. 2016;26(4):374-381. https://doi.org/10.5455/bcp.20160224101558.
[23] Kara Ö, Arık G, Kızılarslanoglu MC, Kılıc MK, Varan HD, Sümer F, Esme M, Altıner S, Kuyumcu ME, Yesil Y, Balam Yavuz B, Cankurtaran M, Halil M. Potentially inappropriate prescribing according to the STOPP/START criteria for older adults. Aging Clin Exp Res. 2016;28(4):761-768. https://doi.org/10.1007/s40520-015-0475-4.
[24] Kayhan Tetik B, Gedik Tekinemre I, Gül HG, Mete B, Hassanlı S, Alhuraibi W. Evaluation of multiple drug using status by sociodemographic characteristics of individuals with chronic disease. TJFMPC. 2018;12(1):13-18. https://doi.org/10.21763/tjfmpc.399950.
[25] Öztürk Z, Uğraş KG. Drug use and polypharmacy in elderly patients. Tepecik Eğit Hast Derg. 2017;27(2):103-108. https://doi.org/10.5222/terh.2017.103.
[26] Öztürk GZ, Ardic C, Toprak D. Frequency of polypharmacy and use of potentially inappropriate medications in the elderly. Turk J Geriatr. 2017;20(4): 296-305.
[27] Gencer MZ, Arica S. Use of polypharmacy and herbal medication on quality of life in elderly patients at Okmeydani hospital’s polyclinics in Istanbul, Turkey. J Pak Med Assoc. 2017;67(6):895-900.
[28] Varlı M BR, Doğan Ş, Uysal H, Subaşı Ş, Toper M, Peksarı S, Keskin S, Mut Sürmeli D, Turgut T, Öztorun HS, Aras S. Ayaktan Geriatrik hastalarda reçetesiz ürün kullanımı. Ankara Med J. 2017;4:226-234. https://doi.org/10.17098/amj.364163
[29] Ates Bulut E, Soysal P, Isik AT. Frequency and coincidence of geriatric syndromes according to age groups: single-center experience in Turkey between 2013 and 2017. Clin Interv Aging. 2018;13:1899-1905. https://doi.org/10.2147/cia.S180281.
[30] Yılmazel G, Büyükkayacı Duman N. Polypharmacy and comorbidities among elderly women. STED. 2018;27(2):80-85.
[31] Öztürk Z. A cross sectional look at medication use in geriatric patients. Kocaeli Med J. 2018;7(3):104-110. https://doi.org/10.5505/ktd.2018.94834.
[32] Unutmaz GD, Soysal P, Tuven B, Isik AT. Costs of medication in older patients: before and after comprehensive geriatric assessment. Clin Interv Aging. 2018;13:607. https://doi.org/10.2147/CIA.S159966.
[33] Dutoglu E, Soysal P, Smith L, Arik F, Kalan U, Kazancioglu RT, Isik AT. Nocturia and its clinical implications in older women. Arch Gerontol Geriatr. 2019;85:103917. https://doi.org/10.1016/j.archger.2019.103917.
[34] Kızmaz M, Kurt B, Kargin N, Döner E. Investigation of polypharmacy prevalence and affecting factors in patients over 65 years presenting to family medicine polyclinic of rural district hospital. Ankara Med J. 2020;20:123-134. https://doi.org/10.5505/amj.2020.46548.
[35] Ertuna E, Arun MZ, Ay S, Koçak FÖK, Gökdemir B, İspirli G. Evaluation of pharmacist interventions and commonly used medications in the geriatric ward of a teaching hospital in Turkey: A retrospective study. Clin Interv Aging. 2019;14:587. https://doi.org/10.2147/CIA.S201039.
[36] Kara E, İnkaya AÇ, Haklı DA, Demirkan SK, Ünal S. Polypharmacy and drug-related problems among people living with HIV/AIDS: a single-center experience. Turk J Med Sci. 2019;49(1):222-229. https://doi.org/10.3906/sag-1807-295.
[37] Kurt M, Akdeniz M, Kavukcu E. Assessment of comorbidity and use of prescription and nonprescription drugs in patients above 65 years attending family medicine outpatient clinics. Gerontol Geriatr Med. 2019;5:2333721419874274. https://doi.org/10.1177/2333721419874274.
[38] Paksoy C, Özkan Ö, Ustaalioğlu BB, Sancar M, Demirtunç R, Izzettin FV, Okuyan B. Evaluation of potentially inappropriate medication utilization in elderly patients with cancer at outpatient oncology unit. J Oncol Pharm Pract. 2019;25(6):1321-1327. https://doi.org/10.1177/1078155218788698.
[39] Tasci I, Safer U, Naharci MI. Multiple Antihyperglycemic drug use is associated with undernutrition among older adults with type 2 diabetes mellitus: a cross-sectional study. Diabetes Ther. 2019;10(3):1005-1018. https://doi.org/10.1007/s13300-019-0602-x.
[40] Özsürekci C, Arslan SS, Demir N, Çalışkan H, Şengül Ayçiçek G, Kılınç HE, Yaşaroğlu ÖF, Kızılarslanoğlu C, Doğrul RT, Balcı C, Sümer F, Karaduman A, Balam Yavuz B, Cankurtaran M, Halil MG. Timing of dysphagia screening in Alzheimer's dementia. JPEN J Parenter Enteral Nutr. 2020;44(3):516-524. https://doi.org/10.1002/jpen.1664.
[41] Aydos TR, Emre Aydıngöz S, Lux KM, Efe OE, İşli F, Aksoy M, Kadı E. Polypharmacy prevalence among geriatric patients in primary healthcare settings across Turkey: a cross-sectional analysis through the nationwide prescription information system. Turk J Geriatr. 2020;23(2):169-179. https://doi.org/10.31086/tjgeri.2020.151.
[42] Arslan M, Keskin Arslan E, Koç EM, Sözmen MK, Kaplan YC. Relationship between frailty and medicine use and polypharmacy in people over sixty-five years of age. Med Bull Haseki. 2020;58(1):33-41. https://doi.org/10.4274/haseki.galenos.2019.5409.
[43] Kucukdagli P, Bahat G, Bay I, Kilic C, Oren MM, Turkmen BO, Karan MA. The relationship between common geriatric syndromes and potentially inappropriate medication use among older adults. Aging Clin Exp Res. 2020;32(4):681-687. https://doi.org/10.1007/s40520-019-01239-x.
[44] Koçyiğit SE, Günay FS, Dost S, Aydın AE. The factors affecting slow gait speed in older adults. DEUHFED. 2020;13(2):108-114.
[45] Topaloğlu US, Özaslan E. Comorbidity and polypharmacy in patients with breast cancer. Breast Cancer. 2020;27(3):477-482. https://doi.org/10.1007/s12282-019-01040-8.
[46] Eyigor S, Kutsal YG, Toraman F, Durmus B, Gokkaya KO, Aydeniz A, Paker N, Borman P. Polypharmacy, physical and nutritional status, and depression in the elderly: do polypharmacy deserve some credits in these problems? Exp Aging Res. 2021;47(1):79-91. https://doi.org/10.1080/0361073X.2020.1846949.
[47] Selcuk A, Sancar M, Okuyan B, Demirtunc R, Izzettin FV. The potential role of clinical pharmacists in elderly patients during hospital admission. Pharmazie. 2015;70(8):559-562.
[48] Aşçı H, Sönmez YS, Saygin M, Cankara FN, Yeşilot Ş, Yıldırım MK. Investigation of the presence of potential drug-drug interactions in the adult intensive care unit: a retrospective study. Med J SDU. 2016;23(3):87-96.
[49] Şenel G, Uysal N, Oguz G, Kaya M, Kadioullari N, Koçak N, Karaca S. Delirium frequency and risk factors among patients with cancer in palliative care unit. Am J Hosp Palliat Care. 2017;34(3):282-286. https://doi.org/10.1177/1049909115624703.
[50] Bahşi R, Öztorun HS, Turgut T, Sürmeli DM, Coşarderelioğlu Ç, Atmış V, Aras S, Varli M. The relationship between polypharmacy and muscle strenght and function in hospitalized elderly patients. Ankara Med J. 2019;19(3):460-467. https://doi.org/10.17098/amj.624716.
[51] Demir I, Belice T. Polypharmacy: As a predictive indicator of mortality and length of stay for geriatric patients charged in ICU. Eurasian J Med. 2020;4(3):315-319. https://doi.org/10.14744/ejmi.2020.51084.
[52] Alkan A, Yaşar A, Karcı E, Köksoy EB, Ürün M, Şenler FÇ, Ürün Y, Tuncay G, Ergün H, Akbulut H. Severe drug interactions and potentially inappropriate medication usage in elderly cancer patients. Support Care Cancer. 2017;25(1):229-236. https://doi.org/10.1007/s00520-016-3409-6.
[53] Abunahlah N, Elawaisi A, Velibeyoglu FM, Sancar M. Drug related problems identified by clinical pharmacist at the Internal Medicine Ward in Turkey. Int J Clin Pharm. 2018;40(2):360-367. https://doi.org/10.1007/s11096-017-0585-5.
[54] Umit EG, Baysal M, Bas V, Asker I, Kırkızlar O, Demir AM. Polypharmacy and potentially inappropriate medication use in older patients with multiple myeloma, related to fall risk and autonomous neuropathy. J Oncol Pharm Pract. 2020;26(1):43-50. https://doi.org/10.1177/1078155219835303.
[55] Atilla ÖD, Çalışkan Tür F, Aksay E, Doğan T, Eyler Y, Akın Ş. Geriatrik künt travma hastalarının klinik özellikleri. Turk J Emerg Med. 2012;12(3):123-128. https://doi.org/10.5505/1304.7361.2012.04127.
[56] Temrel T, Şahin S. Polypharmacy and potentially inappropriate medication use in geriatric patients presenting to the emergency department. Turk J Geriatr. 2019;22(1): 25-31. https://doi.org/10.31086/tjgeri.2019150569.
[57] Kaplan C, Bilge U, Acar N, Ünlüoğlu İ. Determination of polypharmacy and inappropriate drug use in patients aged over 65 years who presented to the emergency department. Turk J Geriatr. 2019;22(3): 287-294. https://doi.org/10.31086/tjgeri.2019.104.
[58] Sancar M, Mutlu BY, Okuyan B, Izzettin FV. Determination of geriatric patients’ drug profile and identify their pharmaceutical care requirements by determining potential risk factors. Eur Geriatr Med. 2011;2(5):280-283.
[59] Silay K, Yalcin A, Akinci S, Gursoy FG, Sener Dede D. Charlson comorbidity Index, inappropriate medication use and cognitive impairment. Wien Klin Wochenschr. 2017;129(21):799-804. https://doi.org/10.1007/s00508-017-1253-4.
[60] Gocer S, Gunay O, Polat T, Ulutabanca RO, Sonkaya ZI. Polypharmacy and associated factors in people living in a nursing home in Kayseri Turkey. Int Med J. 2017;6(4):646-652.
[61] Savran M, Aşçı H. Evaluation of drug profiles in elderly living in nursing homes: Drug-drug interaction analysis. Med J SDU. 2018;25(4):361-369. https://doi.org/10.17343/sdutfd.403187.
[62] Oguzoncul AF, Ercan E, Celebi E. Identification of the drug-use behaviors of the elderly living in nursing homes. Clin Interv Aging. 2018;13:1225. https://doi.org/10.2147/CIA.S123909.
[63] Çakmur H. Frailty among elderly adults in a rural area of Turkey. Med Sci Monit. 2015;21:1232-1242. https://doi.org/10.12659/msm.893400.
[64] Önal Ö, Durukan E. Frequency of polypharmacy and risk factors in the elderly in Burdur. Turk J Geriatr. 2018;21(4): 550-556. https://doi.org/10.31086/tjgeri.2018.61.
[65] Okuyan B, Babi B, Sancar M, Ay P, Yücel E, Yücel A, İzettin FV. Validation of the Turkish version of medication regimen complexity index among elderly patients. J Eval Clin Pract. 2016;22(5):732-736. https://doi.org/10.1111/jep.12526.
[66] Sayın Z, Sancar M, Özen Y, Okuyan B. Polypharmacy, potentially inappropriate prescribing and medication complexity in Turkish older patients in the community pharmacy setting. Acta Clin Belg. 2020;77(2):1-7. https://doi.org/10.1080/17843286.2020.1829251.
[67] Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE. What is polypharmacy? A systematic review of definitions. BMC Geriatr. 2017;17(1):230. https://doi.org/10.1186/s12877-017-0621-2.
[68] Guthrie B, Makubate B, Hernandez-Santiago V, Dreischulte T. The rising tide of polypharmacy and drug-drug interactions: population database analysis 1995-2010. BMC Med. 2015;13:74. https://doi.org/10.1186/s12916-015-0322-7.
[69] Hovstadius B, Hovstadius K, Astrand B, Petersson G. Increasing polypharmacy - an individual-based study of the Swedish population 2005-2008. BMC Clin Pharmacol. 2010;10:16. https://doi.org/10.1186/1472-6904-10-16.
[70] Dong L, Yan H, Wang D. Polypharmacy and its correlates in village health clinics across 10 provinces of Western China. J Epidemiol Comm Health. 2010;64(6):549-553. https://doi.org/10.1136/jech.2008.085415.
[71] Walus AN, Woloschuk DMM. Impact of pharmacists in a community-based home care service: A pilot program. Can J Hosp Pharm. 2017;70(6):435-442. https://doi.org/10.4212/cjhp.v70i6.1718.
[72] Halli-Tierney AD, Scarbrough C, Carroll D. Polypharmacy: Evaluating risks and deprescribing. Am Fam Physician. 2019;100(1):32-38.
[73] TURKSTAT. 2019
[01.09.2022]. Available from: https://data.tuik.gov.tr/Bulten/Index?p=Causes-of-Death-Statistics-2018-30626.
[74] Garfinkel D. Poly-de-prescribing to treat polypharmacy: efficacy and safety. Ther Adv Drug Saf. 2017;9(1):25-43. https://doi.org/10.1177/2042098617736192.
[75] Maher RL, Hanlon J, Hajjar ER. Clinical consequences of polypharmacy in elderly. Expert Opin Drug Saf. 2014;13(1):57-65. https://doi.org/10.1517/14740338.2013.827660.
[76] Rochon PA, Gurwitz JH. Optimising drug treatment for elderly people: the prescribing cascade. BMJ. 1997;315(7115):1096-1099. https://doi.org/10.1136/bmj.315.7115.1096.
[77] Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Ekl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hrobjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst Rev. 2021;10(1):89. https://doi.org/10.1186/s13643-021-01626-4.
[78] Goncuoglu C, Ozdemir N, Kara E, Bayraktar-Ekincioglu A. Polypharmacy in Turkey: Its definition and prevalence over the years. PROSPERO 2021 CRD420212415282021. Available from: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42021241528.
[79] Munn Z MS, Lisy K, Riitano D, Tufanaru C. Methodological guidance for systematic reviews of observational epidemiological studies reporting prevalence and incidence data. Int J Evid Based Healthc. 2015;13(3):147-153. https://doi.org/10.1097/XEB.0000000000000054.

Details

Primary Language

English

Subjects

Clinical Pharmacy and Pharmacy Practice

Journal Section

Research Article

Authors

Cansu Göncüoğlu ^*
0000-0003-1415-4708
Türkiye

Nesligül Özdemir
0000-0003-2551-9549
Türkiye

Emre Kara
0000-0002-7034-4787
Türkiye

Aygin Ekincioğlu
0000-0002-3481-0074
Türkiye

Publication Date

June 28, 2025

Submission Date

July 20, 2022

Acceptance Date

March 4, 2023

Published in Issue

Year 2023 Volume: 27 Number: 4

IZ

https://izlik.org/JA32TM96XR

Cite

RIS / Bibtex

APA

Göncüoğlu, C., Özdemir, N., Kara, E., & Ekincioğlu, A. (2025). Definition and prevalence over the years of polypharmacy in Turkey: A systematic review. Journal of Research in Pharmacy, 27(4), 1474-1487. https://izlik.org/JA32TM96XR

AMA

1.Göncüoğlu C, Özdemir N, Kara E, Ekincioğlu A. Definition and prevalence over the years of polypharmacy in Turkey: A systematic review. J. Res. Pharm. 2025;27(4):1474-1487. https://izlik.org/JA32TM96XR

Chicago

Göncüoğlu, Cansu, Nesligül Özdemir, Emre Kara, and Aygin Ekincioğlu. 2025. “Definition and Prevalence over the Years of Polypharmacy in Turkey: A Systematic Review”. Journal of Research in Pharmacy 27 (4): 1474-87. https://izlik.org/JA32TM96XR.

EndNote

Göncüoğlu C, Özdemir N, Kara E, Ekincioğlu A (July 1, 2025) Definition and prevalence over the years of polypharmacy in Turkey: A systematic review. Journal of Research in Pharmacy 27 4 1474–1487.

IEEE

[1]C. Göncüoğlu, N. Özdemir, E. Kara, and A. Ekincioğlu, “Definition and prevalence over the years of polypharmacy in Turkey: A systematic review”, J. Res. Pharm., vol. 27, no. 4, pp. 1474–1487, July 2025, [Online]. Available: https://izlik.org/JA32TM96XR

ISNAD

Göncüoğlu, Cansu - Özdemir, Nesligül - Kara, Emre - Ekincioğlu, Aygin. “Definition and Prevalence over the Years of Polypharmacy in Turkey: A Systematic Review”. Journal of Research in Pharmacy 27/4 (July 1, 2025): 1474-1487. https://izlik.org/JA32TM96XR.

JAMA

1.Göncüoğlu C, Özdemir N, Kara E, Ekincioğlu A. Definition and prevalence over the years of polypharmacy in Turkey: A systematic review. J. Res. Pharm. 2025;27:1474–1487.

MLA

Göncüoğlu, Cansu, et al. “Definition and Prevalence over the Years of Polypharmacy in Turkey: A Systematic Review”. Journal of Research in Pharmacy, vol. 27, no. 4, July 2025, pp. 1474-87, https://izlik.org/JA32TM96XR.

Vancouver

1.Cansu Göncüoğlu, Nesligül Özdemir, Emre Kara, Aygin Ekincioğlu. Definition and prevalence over the years of polypharmacy in Turkey: A systematic review. J. Res. Pharm. [Internet]. 2025 Jul. 1;27(4):1474-87. Available from: https://izlik.org/JA32TM96XR